GlaxoSmithKline Pharmaceuticals Limited
GLAXO · Pharma · NSE
₹2,410
Current Market Price
Fair Value (DCF)
₹1,778
Margin of Safety
-26.2%
Updated just now
YieldIQ Score
61/100
Piotroski F-Score
7/9
Economic Moat
Wide
Confidence
71%
ROE
47.5%
Debt/Equity
0.00
WACC
9.8%
Market Cap
₹0.41 Lakh Cr
Quality & Valuation
Neutral model outputs — no recommendations.
ROCE
57.3%
Return on capital employed
EV / EBITDA
31.1×
Enterprise multiple
Debt / EBITDA
0.0×
Leverage vs earnings
Interest Coverage
962.7×
EBIT covers interest
Current Ratio
1.79×
Short-term liquidity
Asset Turnover
0.91×
Revenue per ₹ of assets
Revenue CAGR (3Y)
4.5%
3-year revenue growth
Revenue CAGR (5Y)
—
5-year revenue growth
DCF Scenario Analysis
vs CMP ₹2,409.8
Bear case
₹784.66
MoS -207.1%
Base case
₹1,778.28
MoS -35.5%
Bull case
₹1,890.75
MoS -27.5%
Ratio Trends
GLAXO · last 8 annual periods
ROE
47.5%
ROCE
67.7%
Operating Margin
—
Debt / Equity
0.01×
PE
36.7×
EV / EBITDA
24.8×
Historical Financials
GLAXO · Annual, last 5 years· amounts in ₹Cr unless noted
| Metric | 2021 | 2022 | 2023 | 2024 | 2025 | CAGR |
|---|---|---|---|---|---|---|
| Revenue | ₹3199 Cr | ₹3264 Cr | ₹3226 Cr | ₹3442 Cr | ₹3726 Cr | +3.9% |
| EBITDA | — | ₹849 Cr | ₹904 Cr | ₹888 Cr | ₹1328 Cr | +11.8% |
| EBIT | ₹554 Cr | ₹781 Cr | ₹838 Cr | ₹818 Cr | — | +10.2% |
| PAT | ₹358 Cr | ₹1695 Cr | ₹611 Cr | ₹590 Cr | ₹928 Cr | +26.9% |
| EPS (diluted) | ₹21.14 | ₹22.48 | ₹35.87 | ₹34.83 | — | +13.3% |
| CFO | ₹578 Cr | ₹811 Cr | ₹484 Cr | ₹582 Cr | ₹1290 Cr | +22.2% |
| CapEx | — | ₹-34.6 Cr | ₹-44.0 Cr | ₹-31.2 Cr | ₹-24.7 Cr | — |
| FCF | — | ₹776 Cr | ₹440 Cr | ₹551 Cr | ₹1265 Cr | +13.0% |
| Total Assets | — | ₹4633 Cr | ₹3327 Cr | ₹3557 Cr | ₹4108 Cr | -3.0% |
| Total Debt | — | ₹20.1 Cr | ₹15.5 Cr | ₹18.7 Cr | ₹10.0 Cr | -16.1% |
| Shareholders' Equity | — | ₹2663 Cr | ₹1741 Cr | ₹1778 Cr | ₹1951 Cr | -7.5% |
CAGR computed across the visible window. Signs reverse if start value is zero or negative.
Peer Comparison
GLAXO vs 1 closest peer by market-cap band
| Peer | MoS | Score | Verdict | ROE | PE |
|---|---|---|---|---|---|
| PFIZER PFIZER | — | — | Pending | 18.2% | — |
Click a ticker to view its fair-value analysis.
Dividend History
11 ex-dividend events on file. Source: NSE corporate-actions feed.
Total paid (5Y)
₹238.00/sh
Last payout
2025-05-30
₹42.00
Peak payout
₹90.00
Trailing yield
1.74%
Amounts parsed from NSE subject lines; percent-of-face-value declarations are not converted and shown as missing.
Reverse DCF
Market-implied growth
What FCF growth is priced in →
Risk Analysis
Volatility & drawdown
Risk profile of GLAXO →
DuPont
ROE decomposition
Why ROE is what it is →
Technicals
RSI, MACD, MAs
Reference indicators →
News & Filings
Recent activity
BSE filings + news for GLAXO →
Compare
Head-to-head with peers
Compare GLAXO side by side →
Run Full Interactive Analysis
Interactive DCF sliders, sensitivity heatmap, peer comparison, and more.
Analyse GLAXONow →Model estimates using publicly available data. Not investment advice. YieldIQ is not registered with SEBI as an investment adviser or research analyst. Past performance does not guarantee future results.